A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy
Phase 2
Active, not recruiting
- Conditions
- Peanut-Induced AnaphylaxisPeanut HypersensitivityPeanut AllergyImmune System Diseases
- Interventions
- Biological: Placebo
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Aravax Pty Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT05621317
- Locations
- 🇺🇸
Peninsula Research Associates, Rolling Hills Estates, California, United States
🇺🇸Riley Children's Hospital at IU, Indianapolis, Indiana, United States
🇺🇸IAA Clinical Research, Chevy Chase, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath